News
NICE approves Merck’s Keytruda for adult patients with rare triple negative breast cancer
Merck & Co – known as MSD outside the US and Canada – has received a recommendation from The National Institute for Health and Care Excellence (NICE) for its new injectable treatment, Keytruda, with chemotherapy in adults with a rare form of triple negative breast cancer.